Novacyt UK Holdings Limited entered into a scheme of arrangement to acquire Yourgene Health Plc (AIM:YGEN) from BGF Investments LP, managed by BGF Investment Management Ltd. and others for £16.6 million on July 3, 2023. The offer price per share is £5.22 for 3,176,959,792 issued shares. The Acquisition will be financed from the existing cash resources of the Novacyt Group. Transaction is subject to the satisfaction or waiver (as applicable) of the Conditions, including, court, Yourgene health shareholders approval. Stifel Nicolaus Europe Limited consider the terms of the Acquisition to be fair and reasonable. Yourgene Health board recommend unanimously that Scheme Shareholders vote, or procure the vote, in favor of the Scheme at the Court Meeting. The Acquisition is currently expected to complete during Q3 2023.

Stifel Nicolaus Europe Limited, Cairn Financial Advisers LLP acted as financial advisors and Addleshaw Goddard LLP acted as a legal advisor to Yourgene Health. Numis Securities Limited, SP Angel Corporate Finance LLP acted as financial advisors, Stephenson Harwood LLP acted as legal advisor to Novacyt.